BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3
BioVie Inc. shares rose on Wednesday after the clinical-stage drug developer said its SUNRISE-PD Parkinson’s trial had completed the last patient evaluation visit, moving the story from enrollment and dosing toward data. The stock closed at $1.35, up 3.05%, after trading between $1.31 and $1.37. That matters now because BioVie is a small, low-volume biotech whose valuation is tied closely to clinical events. At Wednesday’s close, the company had a market value of about $10.2 million, and trading volume was 19,735 shares, below the 89,680 average shown by Google Finance.